tucatinib,zanidatamab,mirikizumab,trastuzumab,rituximab
eli lilly,seagen,zymeworks,roche,biogen,jazz
['herceptin', 'shine,(-shine 1),(-shine1),(-shine-1)', 'shine i', 'tukysa', 'zanida', 'zanidatamab', 'jazz', 'seagen']
her2-targeted treatments shine in biliary tract cancer at asco. jazz pharmaceuticals' zanidatamab monotherapy and seagen's tukysa in combination with herceptin showed promise in this subset of her2-positive patients. 